Patents by Inventor Yoon-Chi Han

Yoon-Chi Han has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES AND ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD123 AND USES THEREOF
    Publication number: 20230357417
    Abstract: The present invention provides antibodies that specifically bind to CD123. The invention further relates to immunoconjugates (e.g., antibody-drug conjugates, or ADCs) comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and ADCs for the treatment of a condition associated with cells expressing CD123 (e.g., cancer or autoimmune disease).
    Type: Application
    Filed: March 8, 2023
    Publication date: November 9, 2023
    Applicant: Pfizer Inc.
    Inventors: Manoj Baburao CHARATI, Yoon-Chi HAN, Madan KATRAGADDA, Nicole Melissa PICHÉ-NICHOLAS, Lawrence Nathan TUMEY
  • Antibodies and antibody-drug conjugates specific for CD123 and uses thereof
    Patent number: 11613581
    Abstract: The present invention provides antibodies that specifically bind to CD123. The invention further relates to immunoconjugates (e.g., antibody-drug conjugates, or ADCs) comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and ADCs for the treatment of a condition associated with cells expressing CD123 (e.g., cancer or autoimmune disease).
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: March 28, 2023
    Assignee: Pfizer, Inc.
    Inventors: Manoj Baburao Charati, Yoon-Chi Han, Madan Katragadda, Nicole Melissa Piché-Nicholas, Lawrence Nathan Tumey
  • ANTIBODIES AND ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD123 AND USES THEREOF
    Publication number: 20200283536
    Abstract: The present invention provides antibodies that specifically bind to CD123. The invention further relates to immunoconjugates (e.g., antibody-drug conjugates, or ADCs) comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and ADCs for the treatment of a condition associated with cells expressing CD123 (e.g., cancer or autoimmune disease).
    Type: Application
    Filed: October 16, 2018
    Publication date: September 10, 2020
    Applicant: Pfizer Inc.
    Inventors: Manoj Baburao CHARATI, Yoon-Chi HAN, Madan KATRAGADDA, Nicole Melissa PICHÉ-NICHOLAS, Lawrence Nathan TUMEY
  • INHIBITORY RNAS THAT REGULATE HEMATOPOIETIC CELLS
    Publication number: 20110178159
    Abstract: Provided are compositions and methods for preventing, treating, ameliorating or diagnosing conditions or diseases involving a myeloid cell proliferation disorder. Such compositions and methods target miRNA function myeloproliferative diseases. More particularly, such compositions and methods target miR-29a function in myeloid cell proliferation disorders. Also provided are methods for diagnosing risk or presence of a myeloid cell proliferation disorder in a subject.
    Type: Application
    Filed: May 8, 2009
    Publication date: July 21, 2011
    Inventors: Hua Gu, Yoon-Chi Han, Christoph Park, Irving Weissman